419 related articles for article (PubMed ID: 20187807)
21. Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization.
Krishnan R; Goverdhan S; Lochhead J
Clin Exp Ophthalmol; 2009 May; 37(4):384-8. PubMed ID: 19594565
[TBL] [Abstract][Full Text] [Related]
22. Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD.
Moraru A; Pînzaru G; Moţoc A; Costin D; Brănişteanu D
Rom J Ophthalmol; 2017; 61(3):207-211. PubMed ID: 29450400
[No Abstract] [Full Text] [Related]
23. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.
Kim JE; Mantravadi AV; Hur EY; Covert DJ
Am J Ophthalmol; 2008 Dec; 146(6):930-4.e1. PubMed ID: 18775528
[TBL] [Abstract][Full Text] [Related]
24. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
[TBL] [Abstract][Full Text] [Related]
25. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M;
JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991
[TBL] [Abstract][Full Text] [Related]
26. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy.
Yannuzzi NA; Patel SN; Bhavsar KV; Sugiguchi F; Freund KB
Am J Ophthalmol; 2014 Aug; 158(2):319-327.e2. PubMed ID: 24814167
[TBL] [Abstract][Full Text] [Related]
27. INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Storey PP; Ho V; Yeh S; Reddy S; Fang-Yen NH; Pequignot E; Leiby BE; Fineman M; Garg S; Hubbard GB; Hsu J
Retina; 2015 Oct; 35(10):1992-2000. PubMed ID: 26035396
[TBL] [Abstract][Full Text] [Related]
28. EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Sisk RA; Rusia D; Zamora BG; Kuley A; Toussaint BW
Retina; 2019 Oct; 39(10):1959-1964. PubMed ID: 30234855
[TBL] [Abstract][Full Text] [Related]
29. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
Małgorzata F
Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
[TBL] [Abstract][Full Text] [Related]
30. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents.
Pershing S; Bakri SJ; Moshfeghi DM
Ophthalmic Surg Lasers Imaging Retina; 2013; 44(5):460-4. PubMed ID: 24044708
[TBL] [Abstract][Full Text] [Related]
31. Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab.
Loukianou E; Brouzas D; Apostolopoulos M
Int Ophthalmol; 2011 Jun; 31(3):211-3. PubMed ID: 21611879
[TBL] [Abstract][Full Text] [Related]
32. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis).
Sharei V; Höhn F; Köhler T; Hattenbach LO; Mirshahi A
Eur J Ophthalmol; 2010; 20(1):174-9. PubMed ID: 19927267
[TBL] [Abstract][Full Text] [Related]
33. Short-term intraocular pressure changes after intravitreal injection of bevacizumab.
Hollands H; Wong J; Bruen R; Campbell RJ; Sharma S; Gale J
Can J Ophthalmol; 2007 Dec; 42(6):807-11. PubMed ID: 18026202
[TBL] [Abstract][Full Text] [Related]
34. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
Shah AR; Del Priore LV
Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
[TBL] [Abstract][Full Text] [Related]
35. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
Nuzzi R; Tridico F
Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
[TBL] [Abstract][Full Text] [Related]
36. Influence of axial length and postinjection reflux on sustained intraocular pressure elevation as a result of intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Jung JJ; Mrejen S; Freund KB
Retina; 2014 Mar; 34(3):519-24. PubMed ID: 24240557
[TBL] [Abstract][Full Text] [Related]
37. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
[TBL] [Abstract][Full Text] [Related]
38. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab.
Bakri SJ; Pulido JS; McCannel CA; Hodge DO; Diehl N; Hillemeier J
Eye (Lond); 2009 Jan; 23(1):181-5. PubMed ID: 17693999
[TBL] [Abstract][Full Text] [Related]
39. Bilateral simultaneous intravitreal injections in the office setting.
Bakri SJ; Risco M; Edwards AO; Pulido JS
Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
[TBL] [Abstract][Full Text] [Related]
40. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs.
Carnota-Méndez P; Méndez-Vázquez C; Otero-Villar J; Saavedra-Pazos JA
Eur J Ophthalmol; 2014; 24(5):771-7. PubMed ID: 24706353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
